E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies

Front Immunol. 2023 Jul 11:14:1226057. doi: 10.3389/fimmu.2023.1226057. eCollection 2023.

Abstract

With the rapidly increasing incidence of bladder cancer in China and worldwide, great efforts have been made to understand the detailed mechanism of bladder cancer tumorigenesis. Recently, the introduction of immune checkpoint inhibitor-based immunotherapy has changed the treatment strategy for bladder cancer, especially for advanced bladder cancer, and has improved the survival of patients. The ubiquitin-proteasome system, which affects many biological processes, plays an important role in bladder cancer. Several E3 ubiquitin ligases and deubiquitinases target immune checkpoints, either directly or indirectly. In this review, we summarize the recent progress in E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and further highlight the implications for bladder cancer immunotherapies.

Keywords: E3 ubiquitin ligase; bladder cancer; deubiquitinases; immunotherapy; tumorigenesis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinogenesis
  • Cell Transformation, Neoplastic
  • Deubiquitinating Enzymes
  • Humans
  • Immunotherapy
  • Ubiquitin
  • Ubiquitin-Protein Ligases*
  • Urinary Bladder Neoplasms* / therapy

Substances

  • Ubiquitin-Protein Ligases
  • Ubiquitin
  • Deubiquitinating Enzymes

Grants and funding

This work was supported by the Shanghai Sailing Program (20YF1448100), grants from the Science and Technology Commission of Shanghai Municipality (22Y11905200), the “Voyaging Talents” Fund of the Naval Medical University (2021008149), and National Natural Science Foundation of China (82203450, 81772720,81972391).